Chen, Jun-feng
Chen, Shu-ru
Lei, Zi-ying
Cao, Hui-juan
Zhang, Shao-quan
Weng, Wei-zhen
Xiong, Jing
Lin, Deng-na
Zhang, Jing
Zheng, Yu-bao
Gao, Zhi-liang
Lin, Bing-liang http://orcid.org/0000-0003-4069-6287
Funding for this research was provided by:
National Major Science and Technology Projects of China (2018ZX10302204, 2017ZX10203201003)
National Natural Science Foundation of China (81901940, 82070612)
Natural Science Foundation of Guangdong Province (2021A1515010306)
Guangzhou Research Collaborative Innovation Projects (1561000157)
Article History
Received: 6 November 2021
Accepted: 21 March 2022
First Online: 26 May 2022
Declarations
:
: In this study, Sciclone pharmaceuticals, as the Marketing Authorization Holder of Tα-1 in China, reported SAEs to the drug and regulatory and health authorities after being informed by investigators. Sciclone did not play any role in the design, conduct or funding of this study. The authors have no conflict of interest to declare.
: This study conformed strictly to the Ethical Guidelines of the 1975 Declaration of Helsinki. The study protocol was approved by the Ethics Committee on Clinical Trials of the Third Affiliated Hospital of Sun Yat-sen University in 2016. This study is registered at ClinicalTrials.gov (NCT 03082885). Informed consent was obtained from all patients for being included in the study.
: Consent for publication was obtained from all co-authors.